替尔泊肽组合3期研究1年结果发布;一针下调2个“血脂开关”的小核酸药物……
编者按:近年来,多肽、寡核苷酸及相关偶联药物(TIDES)的研发持续提速,创新成果不断涌现。截至2026年11月上旬,美国FDA已批准7款多肽及寡核苷酸类创新药(不包括胰岛素类药物),涉及不同药物类型和疾病领域。随着越来越多TIDES药物进入临床开发及商业化阶段,药物发现、工艺开发和规模化生产之间的高效协同也日益重要。
作为全球医药创新的赋能者,药明康德化学业务旗下WuXi TIDES平台提供整合药物发现合成、CMC开发及生产的全生命周期服务,为全球合作伙伴开发多肽、寡核苷酸及相关化学偶联药物提供支持。为帮助读者持续了解这一快速发展的领域,我们推出TIDES周报,定期梳理代表性研发进展及产业动态,供读者参阅。
本期聚焦:
礼来三重受体激动剂公布3期研究数据,改善肥胖患者膝骨关节炎疼痛
礼来公布了在研三重受体激动剂retatrutide治疗肥胖或超重伴膝骨关节炎疼痛患者的两项3期临床研究最新数据。结果显示,retatrutide在显著减轻患者体重的同时,也改善了其膝关节疼痛症状。
Retatrutide是一款每周一次皮下注射的在研多肽药物,能够同时激活葡萄糖依赖性促胰岛素多肽(GIP)受体、胰高血糖素样肽-1(GLP-1)受体和胰高血糖素受体。通过同时作用于三条代谢调节通路,该疗法旨在改善肥胖及其相关代谢异常。
根据礼来此前公布的顶线结果,采用疗效估计目标分析,在TRIUMPH-4研究中,9 mg retatrutide组治疗68周后的西安大略大学和麦克马斯特大学骨关节炎指数(WOMAC)疼痛评分较基线平均下降4.5分,基于事后分析计算的降幅为75.8%;12 mg组的体重平均降幅达到28.7%。超过八分之一的retatrutide治疗患者在研究结束时报告没有膝关节疼痛。
另一项3期TRIUMPH-1-OA研究的80周数据也显示,根据礼来公布的疗效估计目标分析,retatrutide治疗患者的WOMAC疼痛评分最大平均降幅为4.3分,基于事后分析计算的降幅为73.1%。超过六分之一的治疗患者在研究结束时报告没有膝关节疼痛。两项研究均达到了预设的主要终点。
这些结果值得关注的一个原因在于,肥胖与膝骨关节炎之间存在复杂的相互作用。一方面,体重增加会提高膝关节承受的机械负荷;另一方面,肥胖相关的代谢异常及低度慢性炎症也可能参与关节病变。对于同时患有肥胖和膝骨关节炎的患者而言,减重不仅是体重管理目标,也可能成为改善疼痛和身体功能的重要干预方式。
Retatrutide的研究进一步支持了这一治疗思路。值得注意的是,研究观察到的疼痛改善不能简单归因于某一特定受体的作用,也尚不能据此认定药物具有独立于减重之外的直接改善关节病变的作用。不过,两项大型3期研究均观察到膝关节疼痛改善,为进一步探索多受体激动剂对肥胖相关并发症的治疗价值提供了临床证据。
随着针对肥胖、2型糖尿病、阻塞性睡眠呼吸暂停及膝骨关节炎疼痛等适应症的临床研究取得进展,retatrutide的开发也体现出一个值得关注的方向:代谢疾病药物的研究目标正在从单一指标改善,逐步扩展至减轻肥胖相关的多种疾病负担。
单次给药降低肝脂肪最高80%,靶向CIDEB的小核酸药首次人体结果积极
再生元公布了与Alnylam Pharmaceuticals合作开发的在研siRNA疗法CIDEBsiRNA(此前称为ALN-CIDEB)的首次人体1/2期研究结果。数据显示,单次皮下注射后,患者肝脂肪含量在第36周较基线平均下降58%~80%,其中62%的治疗患者肝脂肪含量降至5%以下,达到研究定义的正常范围。
CIDEBsiRNA靶向编码细胞死亡诱导DFFA样效应蛋白B(CIDEB)的CIDEB基因所产生的信使RNA(mRNA)。CIDEB蛋白参与肝细胞内脂滴形成、脂质储存和脂质转运等过程。通过降低CIDEB基因的表达,研究人员希望减少肝脏内的过量脂肪积累,为代谢功能障碍相关脂肪性肝病(MASLD)提供新的治疗策略。
这款药物的研发亮点之一,在于其靶点选择得到了人类遗传学研究的支持。研究人员此前发现,携带CIDEB基因特定功能缺失变异的人群,发生部分肝脏疾病的风险较低。这一发现提示,降低CIDEB蛋白的功能可能对肝脏具有保护作用,也为使用siRNA药物模拟这一遗传效应提供了科学依据。
此次首次人体研究为这一策略提供了初步验证。研究共纳入30例接受不同剂量CIDEBsiRNA治疗的患者及10例接受安慰剂的患者,主要评价药物的安全性和耐受性,肝脂肪变化为次要终点。
结果显示,在第6周,CIDEBsiRNA各剂量组的肝脂肪含量较基线平均下降49%~72%;至第36周,相对降幅达到58%~80%,对照组的平均降幅为2.9%。此外,93%的治疗患者肝脂肪含量较基线至少下降30%,同时观察到丙氨酸氨基转移酶(ALT)等肝损伤相关指标的改善。
目前,部分用于肥胖及代谢性疾病的多肽药物可通过影响食欲、体重及全身代谢状态等多种机制,改善肝脏脂肪积累。而CIDEBsiRNA则通过降低肝细胞内CIDEB蛋白的表达,探索从肝脏脂肪代谢本身入手治疗疾病的可能性。
这一研究的另一项亮点在于作用的持续时间。单次给药后,患者肝脂肪含量的下降持续至第36周,体现出siRNA药物在长效治疗方面的潜力。对于需要长期管理的慢性代谢性疾病而言,这一结果为未来探索较长给药间隔提供了依据,但具体给药方案仍需后续研究确定。
从人类遗传学发现到靶点验证,再到首次人体研究,这一进展展示了以遗传学证据指导小核酸药物研发的潜力。
一个分子同时抑制两个基因的表达,双靶点siRNA展示降血脂潜力
Arrowhead Pharmaceuticals公布了在研双靶点siRNA疗法ARO-DIMER-PA的1/2a期临床研究中期结果。数据显示,单次给药后,不同剂量组的低密度脂蛋白胆固醇(LDL-C)最大平均降幅达到65%,甘油三酯最大中位降幅达到78%。
ARO-DIMER-PA是一款靶向肝脏的双功能siRNA疗法,采用siRNA二聚体设计,将分别靶向前蛋白转化酶枯草杆菌蛋白酶/kexin 9型(PCSK9)和载脂蛋白C3(APOC3)编码基因所产生的mRNA的两种功能整合于一个药物分子中,以同时抑制PCSK9和APOC3两个基因的表达。
PCSK9蛋白参与调控低密度脂蛋白(LDL)受体的降解,与LDL-C水平密切相关;APOC3蛋白则参与调节富含甘油三酯的脂蛋白代谢。通过同时抑制这两个靶点,ARO-DIMER-PA旨在改善混合型高脂血症患者的多种血脂异常。
此次公布的数据来自1/2a期研究的单次递增剂量部分,涵盖25 mg至400 mg剂量组,共有21例受试者接受ARO-DIMER-PA治疗,10例接受安慰剂。结果显示,在已报告的不同剂量组及随访时间点,循环PCSK9蛋白水平平均降低50%~89%,APOC3蛋白水平平均降低43%~95%;与此同时,LDL-C平均下降26%~65%,甘油三酯中位下降56%~78%。
安全性方面,研究未报告严重不良事件,但400 mg剂量组有1例受试者发生3级晕厥,大多数治疗期间出现的不良事件为轻度至中度。
这项研究的特别之处在于,它并非简单地将两种降血脂药物联合使用,而是尝试在一个药物分子中整合两种靶向功能。
对于混合型高脂血症,这一策略尤其具有研究价值。LDL-C和甘油三酯受到不同代谢机制的调控,仅作用于一条通路未必能够充分改善所有血脂异常。ARO-DIMER-PA通过在一个分子中整合针对PCSK9和APOC3的两种靶向功能,为同时干预两类血脂指标提供了新的设计思路。
从药物开发角度来看,单分子双靶点策略还可能带来其他潜在优势。例如,与分别开发两款siRNA药物并联合使用相比,单一药物分子有望简化给药方案,并为药物开发流程提供新的选择。不过,将两种靶向功能整合到一个分子中,也意味着需要协调不同靶点的抑制程度、作用持续时间及剂量需求,同时解决由此带来的合成、纯化和质量控制挑战。
随着越来越多疾病的治疗需要同时干预多条生物学通路,RNA干扰技术的创新也可能从如何精准沉默一个基因,进一步延伸至如何通过分子设计实现多个靶点的同时调控。
口服多肽治疗银屑病关节炎,3期研究达到主要终点
强生(Johnson & Johnson)公布了口服多肽药物Icotyde(icotrokinra)治疗活动性银屑病关节炎的3期ICONIC-PsA 1研究积极结果。数据显示,第16周时,58%的icotrokinra治疗患者达到美国风湿病学会20%改善标准(ACR20),对照组为41%,研究达到主要终点。
Icotrokinra是一款靶向白细胞介素-23受体(IL-23R)的口服多肽药物,通过阻断IL-23与其受体结合,调节与炎症相关的信号通路。该药此前已获美国FDA批准治疗中重度斑块状银屑病,此次研究则进一步探索其治疗银屑病关节炎的潜力。
ICONIC-PsA 1研究纳入此前未接受过生物制剂治疗的活动性银屑病关节炎成人患者。除主要终点外,第16周时,icotrokinra组达到ACR50和ACR70的患者比例分别为29%和13%,对照组分别为16%和5%。
在基线时存在符合研究标准的皮肤病变的患者中,也观察到皮肤症状改善。第16周时,57%的icotrokinra治疗患者达到研究者整体评估(IGA)评分为0分或1分,即皮损清除或几乎清除的标准,对照组为14%。
第24周时,icotrokinra组达到ACR20、ACR50和ACR70的患者比例分别为69%、40%和18%。研究观察到的安全性结果与该药物此前已建立的安全性特征一致,未发现新的安全性信号。
与传统小分子药物相比,多肽通常具有更大的分子尺寸,部分多肽还能够通过多个相互作用位点与靶标结合。然而,多肽也容易被胃肠道中的消化酶降解,且其口服吸收还受到肠上皮通透性等因素的限制。因此,许多多肽药物需要通过注射方式给药。
Icotrokinra通过多肽分子设计及相关药物性质优化,实现了每日一次口服给药,同时保留了对IL-23R的靶向作用,为解决多肽药物的口服递送挑战提供了新的实例。
这一进展还有另一层意义。IL-23通路已经通过多款注射型生物制剂得到临床验证,而icotrokinra探索的是能否利用一种不同的分子形式,以口服方式干预同一条疾病相关通路。对于需要长期治疗的银屑病关节炎患者而言,如果口服药物能够提供具有临床意义的疾病控制效果,可能带来更灵活的治疗选择。
随着多肽分子设计及口服递送研究持续取得进展,原本主要依赖注射给药的部分治疗策略,正在获得新的开发可能性。
更多研发进展:
Elebsiran联合疗法治疗丁型肝炎,3期研究达到主要终点
Vir Biotechnology公布了在研siRNA疗法elebsiran联合单克隆抗体tobevibart治疗慢性丁型肝炎(CHD)的3期ECLIPSE 1研究积极顶线结果。Elebsiran旨在降低乙肝表面抗原(HBsAg)水平,tobevibart则通过结合HBsAg发挥抗病毒作用。
该研究共纳入124例患者,随机接受每月一次elebsiran联合tobevibart治疗或延迟治疗。结果显示,第48周时,44%的联合治疗患者同时达到丁型肝炎病毒(HDV)RNA检测结果为靶标未检出及丙氨酸氨基转移酶(ALT)水平恢复正常的标准,达到研究主要终点;79%的患者HDV RNA靶标未检出,达到关键次要终点。研究采用延迟治疗对照设计,主要终点比较的是联合治疗组第48周与延迟治疗组第12周的结果。联合疗法总体耐受性良好。Vir Biotechnology计划于2027年年中向美国FDA提交相关监管申请资料。
替尔泊肽联合依奇珠单抗,3b期研究公布一年随访结果
礼来公布了3b期TOGETHER-PsA研究的52周详细结果,评估葡萄糖依赖性促胰岛素多肽/胰高血糖素样肽-1(GIP/GLP-1)双受体激动剂替尔泊肽(tirzepatide)联合白细胞介素-17A(IL-17A)抑制剂依奇珠单抗(ixekizumab)治疗伴有肥胖或超重的活动性银屑病关节炎患者的疗效与安全性。研究设置依奇珠单抗单药治疗作为活性对照。
数据显示,治疗52周后,联合治疗组43.7%的患者达到ACR50应答标准,对照组为15.7%。此外,联合治疗组39.2%的患者同时实现ACR50应答及体重下降至少10%,对照组为1.7%。上述52周结果来自预设的探索性分析,未进行多重比较校正。
寡核苷酸疗法2期结果积极,观察到肌肉功能改善信号
PepGen公布了在研寡核苷酸疗法PGN-EDODM1治疗1型强直性肌营养不良(DM1)的2期FREEDOM2-DM1研究积极结果。PGN-EDODM1旨在作用于疾病相关的异常RNA,改善RNA剪接异常。
在10 mg/kg剂量队列中,8例患者按3:1的比例随机分配至PGN-EDODM1治疗组或安慰剂组,其中6例接受了每4周一次、共4次PGN-EDODM1静脉给药。
结果显示,第13周时,基于22个基因组成的检测,治疗组患者肌肉组织中的异常RNA剪接平均纠正幅度达到46.5%。第16周时,患者的视频评估手部张开时间(vHOT)较基线平均缩短3.9秒,改善幅度达到52.7%,其他肌肉功能指标也呈现积极变化。PGN-EDODM1总体耐受性良好,未报告严重不良事件或剂量限制性毒性。
一体化平台助力TIDES疗法开发
作为医药创新的赋能者,药明康德旗下WuXi TIDES平台为全球合作伙伴开发寡核苷酸、多肽药物及相关化学偶联物,提供高效、灵活和高质量的解决方案。WuXi TIDES通过同一个平台提供覆盖药物发现、CMC开发和生产的全生命周期服务,进一步简化了TIDES药物的开发流程。
平台提供化合物筛选和合成,新型单体、连接子和配体、寡核苷酸、多肽及复杂化学偶联物的工艺开发与任何规模的生产服务。除了化学合成,WuXi TIDES还提供包括脂质纳米颗粒(LNP)在内的各类注射剂型与灌装形式的制剂开发、生产、贴标和配送服务。一体化的分析方法开发、验证和测试平台,能够支持包括原料药及制剂,覆盖从药物发现到临床再到商业化阶段的TIDES药物开发需求。此外,全球申报法规事务药学团队在准备CMC申报资料以支持TIDES新药全球申报方面拥有丰富的经验。
One Molecule, Two Targets: Dual-Target siRNA Shows Promise for Lipid Lowering; Triple Agonist Reduces Knee Pain | TIDES Weekly Editor's Note: In recent years, R&D in peptide and oligonucleotide therapeutics and related synthetic conjugates (TIDES) has accelerated, with new therapeutic approaches continuing to emerge. As of early November 2026, the U.S. FDA had approved seven TIDES drugs this year, spanning multiple therapeutic modalities and disease areas. As TIDES therapies progress through clinical development and toward commercialization, closer coordination across drug discovery, process development, and commercial-scale manufacturing is becoming increasingly important.
As an integral part of of WuXi AppTec, WuXi TIDES is a unique Contract Research and Development Manufacturing Organization (CRDMO) platform. WuXi TIDES offers worldwide partners efficient, flexible, and high-quality solutions for the development of TIDES drugs. The platform greatly simplifies the TIDES drug development by providing all discovery, CMC development and the entire manufacturing supply chain under one roof. The TIDES Weekly Update aims to keep readers informed about this rapidly evolving field by highlighting notable R&D advances and industry developments.
In Focus:
Lilly's Triple-Receptor Agonist Improves Knee Osteoarthritis Pain in Phase 3 Trials Eli Lilly and Company reported new Phase 3 results for its investigational triple-receptor agonist retatrutide in adults with obesity or overweight and knee osteoarthritis pain. The findings showed that retatrutide significantly reduced body weight while also improving knee pain.
Retatrutide is an investigational peptide therapy administered as a once-weekly subcutaneous injection. It simultaneously activates receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. By targeting three metabolic pathways, the therapy is designed to address obesity and related metabolic abnormalities.
According to previously reported topline results from the Phase 3 TRIUMPH-4 trial, patients receiving retatrutide 9 mg experienced a mean 4.5-point reduction in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score at Week 68, corresponding to a 75.8% reduction from baseline in a post hoc analysis. Meanwhile, patients receiving the 12 mg dose achieved a mean weight reduction of 28.7%. More than one in eight retatrutide-treated patients reported being free of knee pain at the end of the study.
Similarly, Lilly's previously reported efficacy-estimand results from the Phase 3 TRIUMPH-1-OA trial showed a mean reduction of up to 4.3 points in WOMAC pain score at Week 80, corresponding to a 73.1% reduction from baseline in a post hoc analysis. More than one in six patients receiving retatrutide reported no knee pain at the end of treatment. Both trials met their prespecified primary endpoints.
These findings are particularly relevant given the complex relationship between obesity and knee osteoarthritis. Excess body weight increases the mechanical load on the knee joints, while obesity-related metabolic abnormalities and chronic low-grade inflammation may also contribute to joint disease. For patients living with both conditions, weight loss may therefore do more than improve weight-related measures: it may also help relieve pain and improve physical function.
The retatrutide results provide further support for this approach. However, the observed improvements in knee pain cannot be attributed to the activation of any single receptor, nor do they establish that retatrutide directly modifies joint disease independently of weight loss. Nevertheless, the improvements observed across two large Phase 3 trials provide clinical evidence supporting further investigation of multi-receptor agonists for obesity-related complications.
Retatrutide's broader development program also points to an evolving direction in metabolic drug development. Beyond weight reduction and glycemic control, researchers are increasingly investigating whether metabolic therapies can address conditions such as obstructive sleep apnea and knee osteoarthritis. The focus is shifting beyond improvements in individual metabolic measures toward reducing the broader burden of obesity-related diseases.
Single-Dose siRNA Therapy Reduces Liver Fat by Up to 80%, Supporting a Genetics-Guided Approach Regeneron Pharmaceuticals reported first-in-human results for CIDEBsiRNA, an investigational siRNA therapy being developed in collaboration with Alnylam Pharmaceuticals and previously known as ALN-CIDEB. Following a single subcutaneous dose, patients experienced mean reductions in liver fat of 58% to 80% from baseline at Week 36. At that time point, 62% of treated patients achieved liver fat levels below 5%, the threshold used to define normal liver fat content in the study.
CIDEBsiRNA targets messenger RNA (mRNA) encoding cell death-inducing DFFA-like effector B (CIDEB), a protein involved in lipid droplet formation, lipid storage, and lipid transport in liver cells. By reducing CIDEB protein expression, researchers aim to limit excessive fat accumulation in the liver, potentially offering a new treatment strategy for metabolic dysfunction-associated steatotic liver disease (MASLD).
An important feature of this program is the human genetic evidence supporting the target. Previous studies have found that individuals carrying certain loss-of-function variants in the gene encoding CIDEB have a lower risk of developing some liver diseases. These findings suggest that reducing CIDEB function may have a protective effect on the liver, providing a scientific rationale for using siRNA to reproduce the effects of these naturally occurring genetic variants.
The first-in-human Phase 1/2 study included 30 patients who received different doses of CIDEBsiRNA and 10 who received placebo. The study primarily evaluated safety and tolerability, with changes in liver fat assessed as a secondary endpoint.
The results offer preliminary clinical support for this strategy. By Week 6, CIDEBsiRNA had produced mean liver fat reductions of 49% to 72% from baseline across the evaluated dose groups. At Week 36, reductions reached 58% to 80%, compared with a mean reduction of 2.9% in the placebo group. In addition, 93% of treated patients achieved at least a 30% reduction in liver fat from baseline, alongside improvements in markers of liver injury, including alanine aminotransferase (ALT).
The approach differs from that of some peptide-based metabolic therapies, which can improve hepatic fat accumulation through their effects on appetite, body weight, and systemic metabolism. CIDEBsiRNA, by contrast, aims to intervene more directly in hepatic lipid metabolism by reducing CIDEB protein expression in liver cells.
The durability of the response is another notable aspect of the findings. Reductions in liver fat persisted through Week 36 following a single dose, highlighting the potential of siRNA therapies to provide sustained effects. For chronic metabolic diseases requiring long-term management, such durability could support the exploration of extended dosing intervals. The optimal dosing regimen, however, remains to be established in future studies.
From human genetic discovery to target validation and now early clinical evidence, this program illustrates how genetics can help guide the development of new oligonucleotide therapies.
One Molecule, Two Targets: Dual-Target siRNA Demonstrates Lipid-Lowering Potential Arrowhead Pharmaceuticals reported interim results from a Phase 1/2a trial of ARO-DIMER-PA, an investigational dual-target siRNA therapy. Following a single dose, mean low-density lipoprotein cholesterol (LDL-C) reductions reached up to 65%, while median triglyceride reductions reached up to 78% across the evaluated dose groups.
ARO-DIMER-PA is a liver-targeted, dual-functional siRNA therapy based on a dimeric design. It integrates two gene-silencing components into a single molecular construct, targeting mRNA transcripts encoding proprotein convertase subtilisin/kexin type 9 (PCSK9) and apolipoprotein C-III (apoC-III).
PCSK9 regulates the degradation of low-density lipoprotein (LDL) receptors and plays an important role in LDL-C metabolism. ApoC-III, meanwhile, is involved in the metabolism of triglyceride-rich lipoproteins. By suppressing the expression of both proteins, ARO-DIMER-PA is designed to address multiple lipid abnormalities in patients with mixed hyperlipidemia.
The interim data came from the single-ascending-dose portion of the Phase 1/2a trial, covering doses ranging from 25 mg to 400 mg. The analysis included 21 participants who received ARO-DIMER-PA and 10 who received placebo.
Across the evaluated dose groups and assessment time points, treatment produced mean reductions of 50% to 89% in circulating PCSK9 protein levels and 43% to 95% in apoC-III protein levels. These changes were accompanied by mean LDL-C reductions of 26% to 65% and median triglyceride reductions of 56% to 78%.
No serious adverse events were reported, although one participant in the 400 mg group experienced Grade 3 syncope. Most treatment-emergent adverse events were mild to moderate.
What makes this approach different is that it goes beyond administering two lipid-lowering treatments together. Instead, it integrates two distinct gene-silencing functions into a single therapeutic molecule.
This approach is particularly relevant to mixed hyperlipidemia. LDL-C and triglycerides are regulated through different metabolic mechanisms, and targeting one pathway alone may not adequately address all lipid abnormalities. By combining activities against PCSK9 and apoC-III, ARO-DIMER-PA offers a new way to address two distinct lipid parameters through a single therapeutic design.
From a drug development perspective, this strategy could offer additional advantages. Compared with using two separate siRNA therapies in combination, a single dual-target construct could simplify dosing and offer new options for drug development.
However, integrating two targeting functions into one molecule also introduces challenges. Developers must balance the degree and duration of target suppression, account for potentially different dose requirements, and address the additional complexities that may arise during synthesis, purification, and quality control.
Whether this approach ultimately delivers advantages in clinical outcomes, manufacturing efficiency, or cost-effectiveness will require further investigation.
As researchers increasingly explore treatments that target multiple disease-related pathways, advances in RNA interference may extend beyond silencing individual genes toward molecular designs capable of suppressing multiple targets simultaneously.
Oral Peptide Meets Primary Endpoint in Phase 3 Psoriatic Arthritis Trial Johnson & Johnson reported positive results from the Phase 3 ICONIC-PsA 1 trial evaluating icotrokinra (marketed as Icotyde), an oral peptide therapy, in adults with active psoriatic arthritis. At Week 16, 58% of patients receiving icotrokinra achieved an American College of Rheumatology 20% response (ACR20), compared with 41% in the placebo group. The trial therefore met its primary endpoint.
Icotrokinra is an oral peptide that targets the interleukin-23 receptor (IL-23R). By preventing IL-23 from binding to its receptor, the therapy modulates inflammatory signaling pathways involved in immune-mediated diseases. Already approved in the United States for eligible patients with moderate-to-severe plaque psoriasis, Icotyde is now being investigated for psoriatic arthritis.
The ICONIC-PsA 1 trial enrolled adults with active psoriatic arthritis who had not previously received biologic therapy. In addition to meeting the primary endpoint, icotrokinra demonstrated improvements across more stringent measures of disease response. At Week 16, ACR50 and ACR70 responses were achieved by 29% and 13% of patients receiving icotrokinra, respectively, compared with 16% and 5% in the placebo group.
Improvements were also observed in patients with qualifying skin involvement at baseline. At Week 16, 57% of icotrokinra-treated patients achieved an Investigator's Global Assessment (IGA) score of 0 or 1, indicating clear or almost clear skin, compared with 14% in the placebo group.
By Week 24, ACR20, ACR50, and ACR70 response rates in the icotrokinra group had increased to 69%, 40%, and 18%, respectively. The observed safety findings were consistent with the therapy's established safety profile, with no new safety signals identified.
Beyond the efficacy results, the development of icotrokinra is notable because it addresses a longstanding challenge in peptide therapeutics: oral delivery.
Compared with conventional small molecules, peptides generally have larger molecular structures, and some can engage their targets through multiple interaction sites. These characteristics can make peptides attractive for targets that are difficult for traditional small molecules to address. However, peptides are also susceptible to degradation by digestive enzymes, while limited intestinal permeability can restrict their absorption. As a result, many peptide therapies must be administered by injection.
Icotrokinra illustrates how advances in peptide design and the optimization of drug-like properties can enable once-daily oral administration while preserving activity against IL-23R. Its development offers an example of how researchers are working to overcome the challenges associated with oral peptide delivery.
There is also a broader therapeutic implication. The IL-23 pathway has already been clinically validated by several injectable biologic therapies. Icotrokinra explores whether the same disease-related pathway can be targeted through a different molecular modality and route of administration.
For patients with psoriatic arthritis who require long-term treatment, an effective oral therapy could offer greater flexibility in disease management. However, differences in efficacy and safety between treatments cannot be established through cross-trial comparisons alone and would require appropriately designed studies.
As peptide design and oral delivery technologies continue to advance, therapeutic approaches that have traditionally relied on injections may become accessible through new routes of administration.
More TIDES Updates:
Elebsiran Combination Meets Primary Endpoint in Phase 3 Hepatitis Delta Trial Vir Biotechnology announced positive topline results from the Phase 3 ECLIPSE 1 trial evaluating the investigational siRNA therapy elebsiran in combination with the monoclonal antibody tobevibart in patients with chronic hepatitis delta (CHD). Elebsiran is designed to reduce hepatitis B surface antigen (HBsAg) levels, while tobevibart binds HBsAg to exert antiviral activity.
The trial enrolled 124 patients who were randomized to receive immediate combination treatment or deferred treatment. At Week 48, 44% of patients receiving the combination achieved both undetectable hepatitis delta virus (HDV) RNA, defined as target not detected, and normalization of ALT levels, meeting the study's primary endpoint. In addition, 79% of patients achieved HDV RNA target-not-detected status, meeting a key secondary endpoint. The primary efficacy comparison used results from the immediate-treatment group at Week 48 and the deferred-treatment group at Week 12.
The combination was generally well tolerated. Vir Biotechnology plans to submit a comprehensive regulatory package to the U.S. FDA in mid-2027.
Tirzepatide Plus Ixekizumab Shows Sustained Benefits in 52-Week Phase 3b Analysis Eli Lilly and Company reported detailed 52-week results from the Phase 3b TOGETHER-PsA trial evaluating tirzepatide, a dual GIP/GLP-1 receptor agonist, in combination with ixekizumab, an interleukin-17A (IL-17A) inhibitor, in adults with active psoriatic arthritis and obesity or overweight. The trial compared the combination regimen with ixekizumab monotherapy.
At Week 52, 43.7% of patients in the combination group achieved an ACR50 response, versus 15.7% in the control group. In addition, 39.2% of patients in the combination group achieved both an ACR50 response and at least 10% weight loss, versus 1.7% in the control group. These 52-week findings came from prespecified exploratory analyses that were not adjusted for multiple comparisons.
Oligonucleotide Therapy Shows Positive Phase 2 Results in Myotonic Dystrophy Type 1
PepGen reported positive Phase 2 results from the FREEDOM2-DM1 trial of PGN-EDODM1, an investigational oligonucleotide therapy for myotonic dystrophy type 1 (DM1). The therapy is designed to target toxic RNA associated with DM1 and correct downstream RNA mis-splicing.
In the 10 mg/kg cohort, eight patients were randomized 3:1 to receive PGN-EDODM1 or placebo. Six patients received four intravenous doses of PGN-EDODM1, administered once every four weeks.
At Week 13, mean correction of RNA mis-splicing in muscle tissue reached 46.5%, as measured using a 22-gene panel. By Week 16, video-assessed hand opening time (vHOT) had decreased by an average of 3.9 seconds from baseline, representing a 52.7% improvement. Positive trends were also observed across other measures of muscle function. PGN-EDODM1 was generally well tolerated, with no serious adverse events or dose-limiting toxicities reported. Given the small sample size, these early signals of functional improvement will need to be confirmed in larger studies.
An Integrated CRDMO Platform for TIDES Drug Development As an integral part of WuXi AppTec, WuXi TIDES, an integrated CRDMO platform, offers clients efficient, flexible, and high-quality solutions for the drug development of oligonucleotides, peptides and related synthetic conjugates. The platform greatly simplifies the TIDES drug development by providing all discovery, CMC development and the entire manufacturing supply chain under one roof.
WuXi TIDES offers discovery synthesis, process development and manufacturing of novel monomers, linkers and ligands, oligonucleotides, peptides and complex synthetic conjugates at any scale. Beyond chemistry, the platform offers formulation development, manufacturing, packaging, labeling and distribution in a variety of oral & injectable dosage forms and filling formats. Its comprehensive analytical method development, validation and testing platform supports TIDES drug development from discovery through clinical to commercial for both drug substance and drug product. Moreover, WuXi TIDES regulatory dossier preparation teams are experienced in global fillings of TIDES molecules with all major regulatory agencies.